Optimize treatment approaches in isocitrate dehydrogenase (IDH) mutant gliomas: open issues

被引：1
|
作者：
Ruda, Roberta [1 ]
机构：
[1] Univ & City Hlth & Sci Hosp, Div Neuro Oncol, Dept Neurosci, Turin, Italy
来源：
NEURO-ONCOLOGY | 2023年 / 25卷 / 01期
关键词：
D O I：
10.1093/neuonc/noac227
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：26 / 27
页数：2
相关论文
共 50 条
  • [31] Cognitive issues in patients with IDH mutant gliomas: from neuroscience to clinical neuropsychology
    Michael W. Parsons
    David S. Sabsevitz
    Journal of Neuro-Oncology, 2023, 162 : 525 - 533
  • [32] Cognitive issues in patients with IDH mutant gliomas: from neuroscience to clinical neuropsychology
    Parsons, Michael W. W.
    Sabsevitz, David S. S.
    JOURNAL OF NEURO-ONCOLOGY, 2023, 162 (03) : 525 - 533
  • [33] FUNCTIONAL CHARACTERISATION OF THE ISOCITRATE DEHYDROGENASE 1 (IDH 1) R132H MUTATION IN GLIOMAS
    Biedermann, J.
    Abou El-Ardat, K.
    Conde, M.
    Wiedemuth, R.
    Peitzsch, M.
    Eisenhofer, G.
    Kunz-Schughart, L.
    Temme, A.
    Schroeck, E.
    Klink, B.
    NEURO-ONCOLOGY, 2014, 16
  • [34] Editorial for "Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features"
    Kugel, Harald
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2021, 53 (05) : 1408 - 1409
  • [35] Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1)
    Kang, Chung Hyo
    Choi, Sang Un
    Son, You Hwa
    Lee, Heung Kyoung
    Jeong, Hye Gwang
    Yun, Chang-Soo
    Ahn, Sunjoo
    Park, Chi Hoon
    ANTICANCER RESEARCH, 2020, 40 (09) : 4929 - 4935
  • [36] Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1
    Davis, Mindy I.
    Gross, Stefan
    Shen, Min
    Straley, Kimberly S.
    Pragani, Rajan
    Lea, Wendy A.
    Popovici-Muller, Janeta
    DeLaBarre, Byron
    Artin, Erin
    Thorne, Natasha
    Auld, Douglas S.
    Li, Zhuyin
    Dang, Lenny
    Boxer, Matthew B.
    Simeonov, Anton
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (20) : 13717 - 13725
  • [37] Ivosidenib Isocitrate dehydrogenase (IDH) inhibitor Treatment of hematological cancer Treatment of solid tumors
    Gras, J.
    DRUGS OF THE FUTURE, 2017, 42 (10) : 617 - 623
  • [38] Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas
    Schaefer, S.
    Behling, F.
    Skardelly, M.
    Koch, M.
    Ott, I.
    Paulsen, F.
    Tabatabai, G.
    Schittenhelm, J.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2018, 44 (02) : 207 - 223
  • [39] Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions
    Upadhyay, Vivek A.
    Brunner, Andrew M.
    Fathi, Amir T.
    PHARMACOLOGY & THERAPEUTICS, 2017, 177 : 123 - 128
  • [40] Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma
    Corrigan, Lynda
    Lowery, Maeve
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 15 (05) : 475 - 481
12345